| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002304640 |
| P356 | DOI | 10.1186/1476-4598-9-196 |
| P932 | PMC publication ID | 2917429 |
| P698 | PubMed publication ID | 20649976 |
| P5875 | ResearchGate publication ID | 45281051 |
| P50 | author | Gema Moreno-Bueno | Q43675726 |
| Camilla Cerutti | Q58762188 | ||
| Maria M Caffarel | Q58887967 | ||
| Eduardo Pérez-Gómez | Q59140272 | ||
| Cristina Sánchez | Q39078704 | ||
| P2093 | author name string | Santos Mañes | |
| José Palacios | |||
| Manuel Guzmán | |||
| Juana M Flores | |||
| Emilia Mira | |||
| Isabel García-Real | |||
| Clara Andradas | |||
| P2860 | cites work | Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation | Q40259864 |
| Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. | Q40568311 | ||
| Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells | Q40910820 | ||
| Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion | Q44883122 | ||
| JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. | Q46613967 | ||
| p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma | Q57009856 | ||
| Emerging roles of proteases in tumour suppression | Q57082634 | ||
| Insights from transgenic mouse models of ERBB2-induced breast cancer | Q80188238 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma | Q28242391 | ||
| Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients | Q28366039 | ||
| Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 | ||
| Genes that mediate breast cancer metastasis to lung | Q29547479 | ||
| Dissemination and growth of cancer cells in metastatic sites | Q29555846 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. | Q33885039 | ||
| Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer | Q34026054 | ||
| The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. | Q34066911 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Cannabinoids: potential anticancer agents | Q34542671 | ||
| Maximizing mouse cancer models | Q34661270 | ||
| Proteases and metastasis: clinical relevance nowadays? | Q36285734 | ||
| A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. | Q36612060 | ||
| Loss of cannabinoid receptor 1 accelerates intestinal tumor growth | Q36922627 | ||
| Cannabinoids for cancer treatment: progress and promise | Q37058660 | ||
| Targeting the endocannabinoid system: to enhance or reduce? | Q37150745 | ||
| Emerging strategies for exploiting cannabinoid receptor agonists as medicines | Q37230665 | ||
| Targeted therapies in breast cancer: where are we now? | Q37327300 | ||
| Her2-positive breast cancer: herceptin and beyond. | Q37330891 | ||
| Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon | Q37371891 | ||
| Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. | Q37381629 | ||
| Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. | Q37523202 | ||
| Tiling path genomic profiling of grade 3 invasive ductal breast cancers | Q39868704 | ||
| Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. | Q40002514 | ||
| Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy | Q40189564 | ||
| Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. | Q40217236 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | breast cancer | Q128581 |
| cannabinoids | Q422936 | ||
| P304 | page(s) | 196 | |
| P577 | publication date | 2010-07-22 | |
| P1433 | published in | Molecular Cancer | Q15724585 |
| P1476 | title | Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition | |
| P478 | volume | 9 |
| Q34074335 | Anandamide inhibits breast tumor-induced angiogenesis |
| Q90305460 | Anti-tumour actions of cannabinoids |
| Q38806270 | Antitumorigenic targets of cannabinoids - current status and implications |
| Q92210214 | Cannabidiol Induces Cell Cycle Arrest and Cell Apoptosis in Human Gastric Cancer SGC-7901 Cells |
| Q47673750 | Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression |
| Q34513406 | Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis |
| Q39163671 | Cannabinoid signaling in health and disease |
| Q89919906 | Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment |
| Q26866298 | Cannabinoids as therapeutic agents in cancer: current status and future implications |
| Q64226446 | Cannabinoids in cancer treatment: Therapeutic potential and legislation |
| Q36473356 | Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation |
| Q35238992 | Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. |
| Q27694715 | Cannabinoids, endocannabinoids, and cancer |
| Q38503842 | Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. |
| Q37164208 | Critical appraisal of the potential use of cannabinoids in cancer management |
| Q28476823 | Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion |
| Q38351132 | Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature |
| Q36558056 | Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists |
| Q26766163 | Endocannabinoids as Guardians of Metastasis |
| Q35069709 | Expression and functional relevance of cannabinoid receptor 1 in Hodgkin lymphoma |
| Q64080447 | Future Aspects for Cannabinoids in Breast Cancer Therapy |
| Q52583978 | INSIGHT ON THE IMPACT OF ENDOCANNABINOID SYSTEM IN CANCER: A REVIEW. |
| Q36408464 | Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential |
| Q58102489 | Medical Use of Cannabinoids |
| Q33636763 | Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. |
| Q36843205 | Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent |
| Q35146525 | Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer |
| Q50675905 | Multilayer photodynamic therapy for highly effective and safe cancer treatment. |
| Q24622202 | Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms |
| Q34298903 | O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms |
| Q37995375 | Off-target cannabinoid effects mediated by GPR55. |
| Q38955546 | Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. |
| Q28075903 | Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents |
| Q38052298 | Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth |
| Q34781231 | Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans |
| Q38889500 | Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer |
| Q38211378 | Selected terpenoids from medicinal plants modulate endoplasmic reticulum stress in metabolic disorders |
| Q34402827 | Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. |
| Q34669534 | The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids |
| Q64072053 | The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet? |
| Q35193299 | The endocannabinoid system and cancer: therapeutic implication |
| Q37393042 | The endocannabinoid system and sex steroid hormone-dependent cancers. |
| Q38469671 | The evolving role of the endocannabinoid system in gynaecological cancer |
| Q64284375 | The onus of cannabinoids in interrupting the molecular odyssey of breast cancer: A critical perspective on UPR and beyond |
| Q84066889 | Towards the use of cannabinoids as antitumour agents |
| Q93006401 | Treatment with Cannabinoids as a Promising Approach for Impairing Fibroblast Activation and Prostate Cancer Progression |
| Q37829751 | Update on the endocannabinoid system as an anticancer target |
Search more.